| Trial ID: | L4690 |
| Source ID: | NCT00908921
|
| Associated Drug: |
Glimepiride
|
| Title: |
Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)
|
| Acronym: |
GREAT
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: GLIMEPIRIDE
|
| Outcome Measures: |
Primary: Change in glycosylated hemoglobin (HbA1c) rate, week 16 | Secondary: Fasting Plasma Glucose (FPG) rate, week 16|Post Prandial Glucose (PPG) rate, week 16|Percentage of patients achieving HbA1c <7.0, week 16
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
391
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2009-04
|
| Completion Date: |
2010-09
|
| Results First Posted: |
|
| Last Update Posted: |
2012-08-08
|
| Locations: |
Sanofi-Aventis Administrative Office, Shanghai, China
|
| URL: |
https://clinicaltrials.gov/show/NCT00908921
|
